TIL News and Press, Instil Bio Inc. From 02/26/24

2024-02-26 07:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-20 07:07:59 ET More on Iovance Biotherapeutics Iovance: Approval For Historic Solid Tumor Targeting TIL Therapy Likely, Outlook Promising Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date Iovance Biotherapeutics: The Ea...

2024-01-25 12:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-17 15:40:30 ET More on Instil Bio Instil Bio announces effective date of 1-for-20 reverse stock split Seeking Alpha’s Quant Rating on Instil Bio Historical earnings data for Instil Bio Financial information for Instil Bio For further de...

2024-01-17 10:00:18 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Health stocks to watch this earnings season as sector poised for resurgence Seeking Al...

DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today anno...

2023-12-27 07:20:21 ET More on Iovance Biotherapeutics Iovance Biotherapeutics: The Easiest Money May Have Been Made, But Approval Does Seem Likely Iovance Biotherapeutics, Inc. (IOVA) Q3 2023 Earnings Call Transcript Iovance Biotherapeutics: Testing Shareholders' Pa...

2023-12-05 17:04:41 ET More on Instil Bio Seeking Alpha’s Quant Rating on Instil Bio Historical earnings data for Instil Bio Financial information for Instil Bio For further details see: Instil Bio announces effective date of 1-for-20 reverse stock...

DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today anno...

2023-11-14 02:18:36 ET More on Instil Bio Seeking Alpha’s Quant Rating on Instil Bio Historical earnings data for Instil Bio Financial information for Instil Bio For further details see: Instil Bio Non-GAAP EPS of -$0.16 misses by $0.01